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hemodialysis patients and nine anephricpatients were compared with the concentrations in 34 normolipidemic subjects. The dialysis patients displayed a moderate hypertriglyceridemia (1.94 ± 0.12 vs 1.09 ± 0.11 mmol/L in controls, mean ± SEM; P <0.001), apo CIII concentrations were also increased (130.2 ± 2.1 vs 108.4 ± 0.7 mg/L; P <0.001), whereas apo CII (34.5 ± 0.5 vs 36 ± 0.5 mgIL; P <0.05), apo E (22.7± 0.3 vs 27.9 ± 0.2 mgIL; P <0.001), and apo A-I (1.18 ± 0.05 vs 1.31 ± 0.04 gIL; P <0.05) were decreased. Concentrations of serum apo B were normal (0.86 ± 0.03 vs 0.97 ± 0.07 gIL). In the hemodialysis patients, apo CIII concentrations were increased in apo B-containing lipoproteins (30.1 ± 0.5 vs 25 .0 ± 0.1 mg/L; P <0.001), whereas CII and E were decreased below control values(14.4± 0.2 vs 16.8 ± 0.1, and 8.2 ± 0.2vs 11.4 ± 0.1 mg/L, respectively; P
<0.001 each). By calculation, non-B-containing
lipoproteins in the hemodialysis group had increased concentrations of apo CIII (100.1 ± 2.1 vs 83.3 ± 0.7 mg/L; P <0.001) and decreased amounts of apo E (14.5 ± 0.4 vs 16.4 ± 0.3 mgIL; P <0.001); apo CII content was unchanged (20.1 ± 0.5 vs 19.3 ± 0.5 mgIL). Results forapo CII, CIII, and E among apo A-I-containing lipoproteins in both normolipidemic and hemodialysis groups were similar to those in non-B-containing lipoproteins. Finally, the sole significant (P <0.01) difference between the anephric and hemodialysis groups was the lower apo E concentrations in the former group. Accumulation of triglyceride-rich lipoproteins in hemodialysis patients may thus be related to the enrichment of apo CIII in apo B-containing lipoproteins and to a marked decrease in the apo CII and E contents.
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Chronic renal failure is clearly associated with a disturbance in lipid metabolism. Numerous studies have been devoted to evaluation of the plasma lipid profile in this pathological state (1) (2) (3) (4) (5) . The mild hypertriglyceridemia of chronic renal failure is considered to be due to an increase in concentrations of circulating very-low-density lipoproteins (VLDL) and theirmetabolic products (6, 7) . The cholesterol content of lowdensity lipoproteins (LDL) is normal, whereas that of high-density lipoproteins (HDL) is decreased (4, (8) (9) (10) . Over recent years, apolipoproteins have been receiving increasing attention in view of their important role in the structural integrity and functional specificity of lipoprotein particles. Most studies have focused on the major apolipoproteins of LDL [i.e., apolipoprotein B (apo B)] and HDL (i.e., apo A-I) so as to understand further the mechanisms underlying the atherogenicity of certain dyslipoproteinemic states (11) (12) (13) (14) (15) (16) (17) . Serum concentrations of apo A-I in uremic patients are generally thought to be less than in control subjects (7) (8) (9) (10) (18) (19) (20) (21) (22) , whereas those of apo B are normal (19) (20) (21) 23) (33) . Thus, an alteration in the total concentrations of these three apolipoproteins in plasma, and especially of their relative proportions within TRL, could affect the clearance rate of these particles. Until now, few studies have been performed to evaluate the concentrations in serum of ape CII, CIII, and E in uremic subjects by use of specific immunoassays (21, 22, 34) . The present study was undertaken to provide more information on the distribution of apo CII, CIII, and E in apo B-containing as well as in non-B-containing and in ape A-I-containing lipoproteins in sera of hemodialysis and anephric patients. We have approached this question by applying a new, specific, enzyme-linked immunosorbent assay (ELISA) technique (35) . with use of ELISA involving antibodies that had been prepared and purified in our laboratory (35, 37) . Briefly, we coated 96-wellmicrotiter plates (Nunc,Polylabo, Strasbourg, France)witheach purified antibody, 500 ng/well(100p.Lofa 5 mg/L solution per well),and incubatedovernight at 4#{176}C. After three successive washings, we pipetted onto the wells 100 L of three different dilutions of each serum sample in phosphate-buffered saline(10mmol/L, pH 7.4) containing 1 mL of Tween Montpellier, France) and characterized by itssimilar affinity for VLDL and LDL (35, 38, 39) . Similarly, the amounts of apo CII, CIII, or E associated with the ape A-I-containing lipoprotein particles were determined by coatingplateswith 4A12, 500 ng/well(100 pL of a 5 mgfL solution), a monoclonal anti-ape A-I antibody produced in mice (Sanofi Research Center) (40) .
MaterIals and Methods

Patients
Other steps in this ELISA were performed as described above, with peroxidase-labeled anti-apeCII,anti-ape Cm, or anti-apo E antibodies, as appropriate, in the last step, to measure the corresponding apolipoproteins in ape B-or in ape-A-I-containing lipoprotein particles. The protein concentrations of purified antibodies and purified apolipoproteins used for construction of the standard curves were determined by use of the classic Lowry technique, with bovine serum albumin as standard (41) . The standard curves were established with purified apo CII, CIII, and E (42) and were used to calculate the concentrations of ape CII, CIII, and E in whole serum and in apo B-and in ape-A-I-containing lipoproteins.
Each Concentrations ofape A-I in serum were significantly lowerinthehemodialysis patients (P <0.05)than inthe control group, whereas total serum ape CII was slightly (4.4%)but significantly (P <0.05) decreasedin the former group, and total serum ape E was markedly (18.6%)decreased(P <0.001). Finally, total concentrations of ape CIII in serum were 20.1% higherin hemo- higher in the women than in the men in this group. As Table 3 shows, the most pronounced difference between anephric patients and our hemodialysis group was the marked decrease in total serum ape E (9.7%; P 
Discussion
Patientswith chronicrenalfailure and who undergo regular hemodialysis display a high prevalence of atherosclerotic disease (43) (44) (45) (46) . However, it is still uncertain whether uremic patients are more prone to develop such disease (47), although they frequently exhibit a more rapidprogression ofalreadyexisting disease (48) . Plasma lipid profiles in chronic renal failure have been widely studied (1) (2) (3) (4) (5) , but only few apolipoprotein profiles have been described (21, 22, 34) . In agreement with previous reports, we have observed that hemodialysis patients display moderate hypertriglyceridemia, normal concentrations of total serum cholesterol (1-5, 21, 22,34, 48) , subnormal apo B, and decreased ape A-I (6,   21, 34, 48, 50) . Furthermore, concentrations of triglycerides and cholesterol were increased in serum of anephric patients.
Regarding the minor apolipoproteins, our patients showed markedly increased total serum concentrations of ape CIII, with characteristic decreasesin ape CII and E as described by others (21, 22, 34, 51, 52) . Studies of the distributionof these apelipeproteinsamong ape B-containing and ape B-free lipeproteins, as originally suggested by Attman et al. (21) , allow a more precise characterization of the uremic dyslipidemiasand their rolein the progressionof atherosclerotic diseasein patients with chronicrenalfailure. To our knowledge, the only published report on this describes ape CIII distribution between ape B-containing and ape B-free lipeprotein particles (22) . In fact, both our own studies and those of Parsy et al. (22) show increased concentrations of ape CIII among the ape B-containing lipoprothins; however, in disagreement with the latter authors (22), we observed that the increase in total serum ape CIIIin hemodialysispatientswas almost equallydistributedbetween the ape B-containingand the ape In additionto the use of a specific immunological method forthe separation ofape B-containing lipeprothins from the ape B-free lipeproteins prior to the determination of CII, CIII, and E concentrations among theseparticles, we have obtainedoriginal information on theCII and E apelipoprotein concentrations inthese two lipeprotein classes. Our results indicate that the decreasedape CIIcontentoftotal serum isfocused only on the ape B-containing lipeproteins, whereas the reductionin totalserum ape E concentration occurred within ape B-containing and ape B-free lipeprotein particles at the same time, but was more pronounced in the ape B-containing lipeproteins (28% vs 11.6%). The latter observations are also true for anephric patients, but the more marked decrease in ape E in this group may confirm a role of the kidney in ape E synthesis and supports the possibility that a reduced renal parenchyma contributes less to the serum pool of ape E than in normal subjects, as alreadyproposedby Blum et al. (56) and Attman et al. (21) . Moreover,themore marked hypertriglyceridemia of these patients than in other hemodialysis subjects may suggest a role for ape E in the dyslipidemias of hemodialysis patients.
However, itremains to be established whether the more marked reduction in anephric ape E concentrations contributes to their increased risk.
Numerous studies have indicated thatboth impaired removal and increased production ofTRL particles contribute to the hypertriglyceridemia of chronicrenal failure (3, 50, (57) (58) (59) (60) . However, more recentstudies suggest that a defective removal of TRL in such patients may be a more significant contributing factor than increased production (3, 7, (21) (22) (23) In fact, in light of our findings documenting an increase of ape CIIIin ape B-containing lipoproteins from hemodialysis patientsand of a reducedPHLA associated with decreased remnant clearance (4, 23, (60) (61) (62) (63) (64) (65) , and in view of the inhibitory roleofape CIIIon lipeprothinlipase activity (26-28) and on thehepaticuptakeof TRL particles (31, 32, 70) , we think that ape CIII may play a key role in the hypertriglyceridemia of hemodialysis patients. However, when anephric patients were compared with the hemodialysisgroup, their more marked hypertriglycendemia was notassociated with a significant increase in ape Cm. Because ape CII is the activator of lipeprotein lipase (24, 25) These authors also showed that incubation of remnants with unfractionated ratape C proteins involvedenrichment with ape CIII but not with ape CII (32, 71) . However,we didnotdetect enrichmentinC-Ilineither ape B-freeor ape A-I-containing lipoproteins in our patients. The accumulation of remnant particles in hemodialysis patients (4, (60) (61) (62) (63) (64) (65) and the factthatthey display a reducedcontentofape E,especially among the apeB-containing lipeproteins, suggesta possible rolefor ape E inhypertriglyceridemia ofhemodialysis patients. Moreover, when comparing anephric patients with the hemodialysis group, we found that their more marked hypertriglyceridemia was associated with a significant decrease in ape E concentrations in totalserum, especially in ape B-containinglipeproteins (P <0.01 and 0.001,respectively). Windler and Havel (71) showed that remnant particles enriched in apo CIIIaredeficient in ape E (32, 71) . Finally, determination oftheapo CII, Cm, and E concentrations among apo A-I-containing lipoproteins (namely,A-I CII,A-I Cm, and A-I E) has indicated that ape B-freeCII,CIII,or E might correspondtoape A-Icontaining CII,Cm, orE, respectively. In factthis could not be the case,because results obtained from a preliminary study indicate the simultaneous presence of particles containing A-Iand B. This suggestion has also been proposed by others (33, 53, 55) .
Thus, determination of CII, CIII, and E apelipoprotein concentrations among the various A-I and B lipoprotein particles would be necessary to evaluatewhether ape B-free CII,CIII, or E corresponds to ape A-I containing A-ICII,A-ICm, orA-IE, respectively, as suggestedby our results.
We concludethat the increased ape CIIIcontent of ape B-containing lipeproteins, associated with the decreased amounts of ape CII and E among these same particles, may lead to an impaired catabolism and (or) disturbed hepaticuptake of TRL. Such a metabolicdysfunction, rather than TRL overproduction,appears to be responsible for hypertriglyceridemia in hemodialysis patients and may be one of the major risk factors for the accelerated atherosclerotic disease typical of hemodialysis patients.
